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ABSTRACT 
Inhibition of human cytochrome P450 2A6 has been demonstrated to play an important role in 
nicotine metabolism and consequent smoking habits. 
Here the “Molecular Lego” approach was used to achieve the first reported electrochemical 
signal of human CYP2A6 and to improve its catalytic efficiency on electrode surfaces. The 
enzyme was fused at the genetic level to flavodoxin from Desulfovibrio vulgaris(FLD) to create 
the chimeric CYP2A6-FLD. Electrochemical characterization by cyclic voltammetry shows 
clearly defined redox transitions of the haem domain in both CYP2A6 and CYP2A6-FLD. 
Electrocatalysis experiments using coumarin as substrate followed by fluorimetric quantification 
of the product were performed with immobilised CYP2A6 and CYP2A6-FLD. Comparison of 
the kinetic parameters showed that coumarin catalysis was carried out with a higher efficiency by 
the immobilised CYP2A6-FLD, with a calculated kcat value significantly higher (P<0.005) than 
that of CYP2A6, while the affinity for the substrate (KM) remained unaltered. The chimeric 
system was also successfully used to demonstrate the inhibition of the electrochemical activity of 
the immobilised CYP2A6-FLD, towards both coumarin and nicotine substrates, by 
tranylcypromine, a potent and selective CYP2A6 inhibitor.  
This work shows that CYP2A6 turnover efficiency is improved when the protein is linked to 
FLD redox module and this strategy can be utilized for the development of new clinically 
relevant biotechnological approaches suitable for deciphering the metabolic implications of 
CYP2A6 polymorphism and for the screening of CYP2A6 substrates and inhibitors. 
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INTRODUCTION 
 
Human cytochrome P450 2A6 (CYP2A6) is a polymorphic Phase I drug metabolising enzyme 
representing up to 10% of total CYPs present in the liver where it is mainly expressed.1 There is 
considerable interest in CYP2A6 primarily due to its leading role in human metabolism of 
nicotine, the addictive agent present in tobacco. About 80 % of nicotine is metabolized by 
CYP2A6, and a clear relationship between CYP2A6 polymorphism and dependence from 
smoking has been demonstrated, together with the consequent risk of lung cancer.2,3 It has been 
widely reported that the individual variability in nicotine metabolism rate, including ethnic group 
and gender related differences, is highly correlated to CYP2A6 genetic polymorphism.2 In 
particular, it has been observed that subjects with a genetic basis for slow CYP2A6 metabolism 
smoke fewer cigarettes and are more likely to stop smoking, compared to individuals with faster 
metabolism.2,3 For these reasons, the use of CYP2A6 inhibitors has been suggested as a possible 
treatment strategy for tobacco-dependent smokers.4 Specifically, CYP2A6 inhibition has been 
proposed for the prevention and treatment of tobacco dependence, to facilitate pharmacological 
approaches such as nicotine replacement therapy by promoting exposure reduction, enhancing 
treatment efficacy, and reducing the susceptibility to carcinogens.4 
Amongst drugs and xenobiotics that can be suitable for CYP2A6 inhibition, methoxsalen, a 
clinically approved drug for the treatment of psoriasis, has been proposed to reduce smoking 
behaviour5 but it may not be selective for CYP2A6 and the risk of undesirable drug-drug 
interactions may be relevant. As a natural remedy, also grapefruit juice, whose inhibitory 
characteristic of CYPs is well established, has been proposed in a clinical study.6 Other attempts 
have also been made by producing synthetic CYP2A6 inhibitors by mimicking the chemical 
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structure of nicotine.7 The discovery and improvement of new powerful and selective CYP2A6 
inhibitors with low or no risk of undesirable side effects is an ongoing research area. Therefore 
the development of new bioanalytical methods suitable for the screening of CYP2A6 substrates 
and inhibitors together with metabolic implications of CYP2A6 polymorphism is extremely 
desirable and of high clinical relevance:this is the aim of the present work. 
A well known substrate of CYP2A6 is coumarin. In humans around 80% of coumarin is 
metabolised by CYP2A6 and its 7-hydroxylation is commonly used both in vitro and in vivo as a 
probe of CYP2A6 activity.1 Coumarins belong to the wide class of plant-derivative 
benzopyrones and are the simplest member of this chemical family of compounds. Medical 
importance of coumarin derivatives is related to their wide function multiplicity that can be 
translated to high pharmacological potential.8 Firstly, coumarin derivatives are extensively used 
as anti-coagulant and anti-thrombotic agents.9,10 Coumarin can also act as anti-inflammatory and 
anti-oxidant agent11 as well as anti-bacterial and anti-viral agent.8 In addition, coumarin has been 
shown to have neuroprotective capabilities against neurodegenerative disorders such as 
Alzheimer’s and Parkinson’s diseases through the inhibition of acetylcholinesterase activity.12,13 
They also have pronounced anti-HIV activity and have been proposed in combination with other 
anti-HIV drugs for therapeutic purposes.14 Lastly, a number of natural and synthetic coumarins 
have been shown to have clinically relevant anticancer activities.8 
Owing to their biotechnological potential and relevance to drug metabolism, CYPs have 
received considerable attention for the development of bio-electrochemical platforms suitable for 
substrate and inhibitor screening.15-24 
Particular interest has been focused on the improvement of the electronic coupling of the 
enzyme with the electrode surface and of its catalytic efficiency. In a fully coupled system 
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reducing equivalents and molecular oxygen consumed are stoichiometrically equivalent to the 
product formed. In uncoupled systems, reducing equivalents and molecular oxygen are not used 
exclusively for product formation leading to the production of superoxide and hydrogen peroxide 
by-products and resulting in an impairment of the enzyme catalytic activity.20 
In order to address the difficulties, significant improvement has been achieved by optimising 
advanced methods for electrode surface modification in conjunction with the development of 
appropriate protein engineering strategies.20,21,23 To this end, our group has previously developed 
and implemented the so-called “molecular Lego” approach25-29 based on the genetic fusion of 
electron transfer modules such as Desulfovibrio vulgaris flavodoxin (FLD) to the CYP of interest 
resulting in active multi-domain P450 enzymes. In particular, it has been demonstrated that using 
artificial redox chains it is possible to regulate the electron flow from the electrode to the 
catalytic domain by mediation of the artificial reductase domain thus enhancing coupling 
efficiency and catalytic activity.20,30 
Here we apply the “molecular Lego” approach to improve the catalytic efficiency of CYP2A6 
by fusing it, at the genetic level, with FLD redox module, chosen for its high sequence similarity 
to the FMN binding domain of the class II CYP reductases.25 Electrochemical study of CYP2A6-
FLD is performed by immobilising the fusion protein on poly-diallyldimethylammonium 
chloride (PDDA) modified glassy carbon electrode and results obtained are compared to those 
relative to CYP2A6 enzyme as a control. The rate of electron flow through CYP2A6-FLD redox 
chain is also estimated by applying Laviron’s theory31 using cyclic voltammetry. Furthermore, 
the catalytic performance of CYP2A6-FLD is investigated using the well known substrate 
coumarin. We examine CYP2A6-FLD turnover efficiency in the presence of coumarin by 
chronoamperometric electrocatalysis on the glassy carbon immobilised enzyme in comparison to 
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CYP2A6. In addition, coupling efficiency of the enzyme is examined during coumarin 
electrocatalysis by on-line measurement of hydrogen peroxide formed using screen-printed 
platinum electrode. Finally, the inhibition of immobilised CYP2A6-FLD in the presence of 
tranylcypromine, a potent and selective CYP2A6 inhibitor is demonstrated towards coumarin 
and nicotine electrocatalysis. 
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EXPERIMENTAL	  SECTION	  
 
Chemicals. Analytical grade chemicals were used with no further purification. All solutions 
were prepared with ultra pure deionised water. Coumarin, 7-hydroxy-coumarin, nicotine, 
tranylcypromine (Sigma-Aldrich) and nicotine-Δ1’(5’)-iminium diperchlorate salt (Biozol) 
solutions were prepared just before use by dissolving the adequate amount in the appropriate 
solvent. Poly-diallyldimethylammonium chloride (PDDA) (Sigma-Aldrich) was used without 
dilution.  
Engineering, expression and purification of CYP2A6 and CYP2A6-FLD. Cyp2A6 gene 
was modified at the 5’-end, corresponding to the N-terminal of the protein, in order to remove 
the hydrophobic membrane anchor by deleting the first 22 aminoacids using the primer 2A6 FW 
reported below. This was done with the aim of improving the expression and stability of the 
construct, as previously reported.32 The cyp2A6 gene was amplified by PCR using the forward 
and reverse primers (restriction enzyme sites shown in bold) and subsequently ligated into the 
pCW expression vector. 
2A6 FW 
5’CAA GAT ACT ACC CAT ATG GCG AAA AAG ACC TCG AGC AAG GGG AAG CTG 
3’ 
2A6 RV 
5’ TTC CTG CCC CGC CAC CAT CAC CAT TGA AAG CTT GCG AGG GCT 3’ 
Cyp2A6-FLD was cloned into pCW expression vector starting from CYP2A6 clone. Two 
primers, reported below, were used to amplify and modify the existing Cyp2A6 in order to delete 
the stop codon and to insert a unique AvrII restriction site. The AvrII restriction site allowed for 
 9 
the cloning of the modified Cyp2A6 gene into the pCW expression vector already containing the 
sequence coding for the FLD gene.27,28 
2A6 FW 
5’CAA GAT ACT ACC CAT ATG GCG AAA AAG ACC TCG AGC AAG GGG AAG CTG 
3’ 
2A6 RV  
5’ CCA CGA AAC TAC ACC ATG AGC TTC CTG CCC CGC CCT AGG AAT TAA 3’ 
Both clones were sequenced in order to confirm the correct amino acid sequence. As 
previously reported27,28 CYP2A6 and CYP2A6-FLD fusion proteins were expressed in E. coli 
DH5α cells with a six histidine tag at the C-terminus. The resulting recombinant proteins were 
purified by coupling ionic exchange (DEAE fast flow) and Ni-affinity chromatography. Both 
CYP2A6 and CYP2A6-FLD were stored in 50 mM phosphate buffer pH 7.4 with 20% glycerol 
at -20°C. 
Fourier transform infrared spectroscopy (FTIR). Infrared spectra of CYP2A6 were 
acquired using attenuated total reflectance (ATR) tool (Harrick Scientific Products, USA). 
Protein samples were prepared on gold-PET flat surface substrates following the same procedure 
described for glassy carbon electrodes and compared with samples prepared by gently mixing 
equal volumes of enzyme solution and buffer (50 mM phosphate buffer pH 7.4 with 20% 
glycerol). Before the FTIR analysis, samples were kept overnight at 4°C. All spectra were 
collected from 4000 to 800 cm-1 using a Bruker Model Tensor 27 FT-IR spectrometer (Bruker 
Instruments, USA) with a scan velocity of 10 kHz and a resolution of 4 cm-1.33 During data 
acquisition, the spectrometer was continuously purged with nitrogen at room temperature. Data 
were collected in triplicates and spectra were averaged using the Opus software (Bruker 
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Instruments, USA). Spectra of the protein were collected in triplicate, subsequently averaged and 
then corrected by subtraction of control samples acquired under the same scanning and 
temperature conditions. In particular, IR spectra of buffer or PDDA, were used with the same 
dilution as background for enzyme samples. 
Immobilisation on glassy carbon electrodes. Both CYP2A6 and CYP2A6-FLD proteins 
were immobilised on PDDA modified glassy carbon electrodes (diameter of 0.07 cm2- BASi, 
UK). To this end, a 1:1 mixture of PDDA: protein was cast onto clean glassy carbon electrodes 
and allowed to set overnight at 4 °C. 
Cyclic voltammetry and chronoamperometry. All electrochemical experiments were carried 
out at room temperature (25 °C) and in 50 mM phosphate buffer pH 7.4, containing 100 mM 
KCl as supporting electrolyte, using an Autolab PGSTAT12 potentiostat (Ecochemie, The 
Netherlands) controlled by GPES3 software. A conventional three-electrode glass cell, equipped 
with a platinum wire counter electrode, an Ag/AgCl (3 M NaCl) reference electrode and 3 mm 
diameter glassy carbon working electrode (BASi, UK), was also used. 
Electrochemical investigation of CYP2A6 and CYP2A6-FLD properties was performed by 
cyclic voltammetry and the potential was scanned between 400 and -850 mV at a scan rate of 
120 mV/sec. Cyclic voltammetry experiments were performed in a nitrogen atmosphere within a 
glovebox (Belle Technologies, UK). 
Electrochemically driven substrate catalysis by CYP2A6 and CYP2A6-FLD was performed 
using chronoamperometry with an applied potential bias of -650 mV for 30 min. In order to 
assure the substrate permeation into the enzymatic layer and minimize mass transport influence 
at the transducer surface, both CYP2A6 and CYP2A6-FLD were immobilised through PDDA on 
glassy carbon rotating disk electrodes. All chronoamperometric electrocatalysis experiments 
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were performed at 200 rpm rotation speed using a BASi RDE-2 rotator system (Bioanalytical 
Systems Inc., USA). Chronoamperometric procedure was applied on freshly prepared electrodes 
in the presence of increasing concentrations of substrate and the product obtained after the 30 
min reaction was immediately quantified by fluorescence spectroscopy detection in the case of 
coumarin and by high performance liquid chromatography (HPLC) in the case of nicotine. 
The coupling efficiency of the immobilised enzymes was measured during the electrocatalysis 
of coumarin (saturating concentration = 10 µM) using the above-mentioned procedure. In 
particular, the amount of hydrogen peroxide produced was estimated using miniaturised screen-
printed platinum electrodes (BVT Technologies, Czech Republic) by sampling, every 5 min, 30 
µL of the electrocatalysis solution. Hydrogen peroxide quantification was performed on platinum 
screen-printed electrode, after calibration with standard solutions, in chronoamperometry by 
applying a potential of 600 mV for 5 min and by measuring the steady state current. Hydrogen 
peroxide concentration was estimated using the calibration curve after volume appropriate 
correction. As a control experiment, ethanol (used for dissolving coumarin) was added instead of 
the substrate to both CYP2A6 and CYP2A6-FLD electrodes. 
Inhibition studies were carried out on CYP2A6-FLD glassy carbon electrodes using 
chronoamperometry, with the same parameters mentioned above for coumarin and nicotine 
electrocatalysis. Inhibition experiments were performed in the presence of coumarin (10 µM) or 
nicotine (150 µM) as the substrate and increasing concentrations of tranylcypromine (from 0.01 
to 100 µM) as the inhibitor. The decrease in the amount of 7-hydroxy coumarin formed in the 
presence of the tranylcypromine inhibitor during coumarin electrocatalysis, was calculated by 
fluorescence spectroscopy. The decrease in the amount of nicotine-Δ1’(5’)-iminium ion formed 
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in the presence of the tranylcypromine inhibitor during nicotine electrocatalysis, was estimated 
by HPLC. 
Fluorescence spectroscopy. Following the termination of the chronoamperometric 
experiments in the presence of different concentrations of the substrate coumarin, the 
electrochemical cell contents were transferred to a fluorimeter for the subsequent 7-hydroxy 
coumarin product quantification. Fluorescence spectra were recorded at room temperature with a 
Perkin Elmer LS 55 fluorescence spectrometer (Perkin Elmer, USA). Excitation wavelength was 
set at 325 nm and emission was monitored between 400 nm and 600 nm with a detected 
maximum emission at 450 nm. Excitation and emission slits size were set at 4 nm and 6 nm, 
respectively. 
HPLC. The quantification of nicotine electrocatalysis product formation was achieved by 
HPLC coupled with a diode array UV detector (Agilent-1200, Agilent technologies, USA) 
equipped with a 4.6 x 150 mm 5 µm Eclipse XDB-C18 column. For this purpose, standard 
solutions of nicotine and Δ1’(5’)-iminium ion were separated using a linear gradient elution 
programmed as follows: linear gradient elution from 20% to 50% acetonitrile and 80% to 50 % 
20 mM phosphate buffer pH 7, 0-10 min; isocratic elution of 50% acetonitrile and 50% 20 mM 
phosphate buffer pH 7, 10-24 min; linear gradient elution to 20% acetonitrile and 80% 20 mM 
phosphate buffer pH 7, 24 min-end of the run. Flow rate was set to 1 mL/min. Detection 
wavelength was set to 257 nm. Retention times were 3 min and 21 min for Δ1’(5’)-iminium ion 
and nicotine, respectively. 
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RESULTS	  AND	  DISCUSSION	  
 
CYP2A6 and CYP2A6-FLD were expressed in E. coli and purified using the protocols 
established in our lab for other CYPs and reported previously.27 Reduction of the haem followed 
by bubbling of carbon monoxide in both purified proteins showed a complete spectral shift of the 
Soret peak at 418 nm to the expected 450 nm, indicating the presence of an active enzyme.  
Prior to the electrochemical experiments ATR-FTIR analysis was carried out to assess the 
structural integrity of the catalytic domain in the presence and in the absence of the cationic 
polyelectrolyte PDDA (Poly-diallyldimethylammonium chloride). In particular, the spectral 
region included between 1450 and 1750 cm-1 was considered, containing information on protein 
secondary structure composition. As shown in Figure 1, spectra obtained for both CYP2A6 in the 
absence and in the presence of PDDA are essentially similar and exhibit the amide I and II 
bands, which are characteristics of secondary structure of proteins.34 Amide I band (~1650 cm-1) 
consists of a group of overlapped signals, mainly due to the peptidic carbonyl group stretching 
mode with a minor contribution from the out-of-phase C-N stretching vibration.34 Grouped bands 
centred at around 1550 cm-1 are commonly assigned to the amide II band, which corresponds to 
the out-of-phase combination of the peptidic N-H in plane bend and the C-N stretching vibration. 
Additionally, the peak at 1517 cm−1 can be assigned to the C-C stretch and C-H bend of side 
chain tyrosine residues.34 Moreover, a set of bands that can be assigned to the amide III mode is 
well detectable in the region between 1200 and 1400 cm-1, these signals are related to the in-
phase combination of the peptidic N-H and C-N bonds bending vibration.34 
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Figure 1. FTIR spectra of A) CYP2A6, B) CYP2A6 in the presence of PDDA. Spectra were 
collected in triplicates and subsequently averaged and corrected by background subtraction. 
 
The ATR-FTIR data shows that the catalytic domain is not denatured upon immobilisation and 
that the secondary structure of CYP2A6 is not affected by the presence of PDDA. Subsequently, 
direct electrochemistry of both enzymes was performed using cyclic voltammetry on PDDA 
modified glassy carbon electrodes. Cyclic voltammograms of CYP2A6 and CYP2A6-FLD 
collected under anaerobic conditions are reported in the Figure 2 where a redox couple 
corresponding to haem FeIII/II transition having a midpoint potential of about -230 mV is shown. 
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Figure 2. Anaerobic cyclic voltammograms of CYP2A6 (A) and CYP2A6-FLD (B) on PDDA 
glassy carbon electrodes. Shown are the original and baseline corrected (upper traces) cyclic 
voltammograms. Scan rate: 120 mV s-1 in in 50 mM potassium phosphate pH 7.4 with 100 mM 
KCl at 25 °C. 
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An additional redox couple is observed in the cyclic voltammogram of CYP2A6-FLD and is 
assigned to the semiquinone–hydroquinone transition of the FMN cofactor with a midpoint 
potential of about -660 mV. No voltammetric peaks are observed in the absence of enzyme (data 
not shown). Peak-to-peak separation of about 130 mV for the haem FeIII/II transition and 180 mV 
for the FLD semiquinone-hydroquinone indicate a quasi-reversible electrochemical processes 
typical of slow electron transfer kinetics. The electron transfer rate constant (ks) was also 
calculated from empirically fitted Laviron’s equations.31 In particular, irreversible 
electrochemistry of both CYP2A6 and CYP2A6-FLD PDDA immobilised proteins was studied 
in cyclic voltammetry by increasing the scan rate from 0.2 to 0.5 V s-1 and the cathodic and 
anodic peak potentials were plotted versus the logarithm of the scan rate. The ks values were 
calculated from the intercept of the E plot versus lnν and were determined to be 0.13 s-1 for 
CYP2A6 and 0.08 s-1 for CYP2A6-FLD. As previously reported,23 low electron transfer rate is 
essential for electrochemically-driven catalysis of P450 systems because it allows for the fine 
tuning of the electron delivery from the reductase to the haem catalytic site. A summary of 
electrochemical data calculated for CYP2A6 and CYP2A6-FLD is reported in Table 1. 
 
Table 1: Redox properties of CYP2A6 and CYP2A6-FLD immobilised on glassy carbon 
electrodes modified with PDDA. 
 Ec (mV) Ea (mV) Em (mV) ΔE (mV) ks (s-1) 
CYP2A6 -294 ± 8 -174 ± 2 -234 ± 5 121 ± 7 0.13 
CYP2A6-
FLD 
-321 ± 12 -128 ± 4 -225 ± 4 134 ± 15 
0.08 
-753 ± 7 -572 ± 6 -662 ± 6 181 ± 10 
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The activity of both CYP2A6 and CYP2A6-FLD using coumarin as the marker substrate was 
investigated by chronoamperometric delivery of reducing equivalents to the immobilised 
enzymes in the presence of increasing concentrations of this substrate. Fluorescence detection 
was then used to quantify the 7-hydroxy coumarin product35 with an excitation wavelength of 
325 nm and an emission wavelength of 463 nm as described in the Methods section. The results 
obtained using CYP2A6 and CYP2A6-FLD glassy carbon electrodes in the presence of 
increasing concentrations of coumarin are shown in Figure 3A and 3B, respectively.Michaelis-
Menten curves for the turnover of both CYP2A6 and CYP2A6-FLD in the presence of coumarin 
were obtained by plotting the rate of product formation versus the relative coumarin 
concentrations (Figure 3C). As can be seen from the figure, a significant difference between 
CYP2A6 and CYP2A6-FLD was observed in the presence of coumarin, also confirmed by one-
way ANOVA followed by post hoc Tukey test (P < 0.001). KM and kcat values for the 
electrocatalysis of coumarin were calculated to be 1.03 ± 0.05 µM and 0.17 ± 0.01 min-1 for 
CYP2A6 and 1.00 ± 0.28 µM and 0.28 ± 0.01 min-1for CYP2A6-FLD. Performing student’s t-
test, no differences were found when evaluating KM values, whereas a significant difference 
between CYP2A6 and CYP2A6-FLD was found when comparing kcat values. In particular, the 
kcat value of coumarin electrocatalysis was significantly higher for CYP2A6-FLD than for 
CYP2A6 (P < 0.005). 
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Figure 3. Formation of 7-hydroxycoumarin by CYP2A6 (A) and CYP2A6-FLD (B) 
immobilised on PDDA glassy carbon electrodes detected by fluorescence spectroscopy. C) Plot 
of reaction velocity versus substrate concentration fitted to Michaelis-Menten equation for 
CYP2A6 (circles) and CYP2A6-FLD (triangles). Data are shown as mean ± SD of three different 
electrodes. 
 
Kinetic values obtained for CYP2A6 have been compared in Table 2 with previously 
published results for coumarin catalysis.36-39 Since to our knowledge this is the first report of the 
immobilisation of CYP2A6, the values reported in the latter table are those of the recombinant 
enzyme free in solution and not immobilised. Regarding the KM values, our results were found to 
be in the same range as those of literature (1-2 µM), confirming the preservation of protein 
affinity for the substrate. However, the electrochemical kcat values for both proteins were found 
to be lower than the values reported for CYP2A6 free in solution. It must be noted that in general 
the non-oriented immobilisation of enzymes on electrodes does affect the turnover number since 
not all the enzymes are within distances that allow for electron transfer and this is not unique to 
the system described here. More interesting though is the comparison between the two 
immobilised proteins where the chimeric enzyme shows a higher catalytic efficiency (kcat/KM) to 
that of the CYP2A6 i.e. 0.28 versus 0.17 min-1 µM-1.  
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Table 2: Comparison of calculated kinetic parameters for coumarin catalysis by immobilised 
CYP2A6 and literature data determined on recombinant enzyme (Rec.) free in solution. 
 KM (µM) kcat (min-1) Variant, Host 
Present work: 
2A6 
2A6-FLD 
 
 
1.03 ± 0.05 
1.00 ± 0.28 
 
 
0.17 ± 0.01 
0.28 ± 0.01 
 
Rec., E. Coli 
Soucek, 1999 [36] 1.48 ± 0.37 3.36 ± 0.18 Rec., E. Coli 
He et al., 2004 [37] 2.17 ± 0.63 3.23 Rec., Spodoptera frugiperda 
Fukami et al., 2005 [38] 1.00 ± 0.10 5.2 ± 0.3 Rec., E. Coli 
Yun et al., 2005 [39] 1.80 ± 0.70 4.5 ± 0.5 Rec., E. Coli 
 
An evaluation of the coupling efficiency of immobilised CYP2A6 and CYP2A6-FLD was also 
carried out by measuring the hydrogen peroxide production during coumarin electrocatalysis. 
The chronoamperograms of sampled solutions during electrocatalysis of CYP2A6 and CYP2A6-
FLD obtained using screen-printed platinum electrodesare shown in Figure 4 (A and B). 
Hydrogen peroxide production profiles (Figure 4C) were obtained by plotting the calculated 
hydrogen peroxide concentration values versus time for both coumarin electrocatalysis and 
control experiments (in the presence of only ethanol- coumarin solvent). The different hydrogen 
peroxide production profiles were compared by two way ANOVA followed by post hoc Tukey 
test which showed that hydrogen peroxide produced during coumarin electrocatalysis was 
significantly higher for immobilised CYP2A6 than CYP2A6-FLD (P < 0.001). Furthermore, on 
CYP2A6 glassy carbon electrodes hydrogen peroxide was produced in statistically higher 
amounts during coumarin electrocatalysis than during control experiments in the presence of 
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only buffer (P < 0.001). However, no significant differences were found when comparing 
hydrogen peroxide production during coumarin electrocatalysis and control experiments on 
CYP2A6-FLD glassy carbon electrodes confirming that the chimeric protein is more coupled. 
The latter observation is also supported by the fact that the immobilised CYP2A6-FLD yields 
double the amount of 7-hydroxycoumarin product when compared to CYP2A6 alone, as 
mentioned earlier (Table 2). 
 
 
Figure 4. Estimation of the amount of hydrogen peroxide produced during coumarin 
electrocatalysis by CYP2A6 (A) and CYP2A6-FLD (B) performed on screen-printed platinum 
electrode. C) Hydrogen peroxide production profile during coumarin electrocatalysis (filled 
symbols) and control experiments (empty symbols) on immobilised CYP2A6 (circles) and 
CYP2A6-FLD (triangles) on glassy carbon electrodes. 
 
The data obtained demonstrate that the regulation of electron flow to the haem of immobilised 
CYP2A6 when genetically fused to D. vulgaris FLD significantly enhanced both coupling and 
catalytic efficiencies of this enzyme towards coumarin hydroxylation.  
Finally, the improved catalytic efficiency of CYP2A6 when genetically fused to FLD was 
examined toward enzyme inhibition in the presence of tranylcypromine, a potent and relatively 
 21 
selective inhibitor of CYP2A6.1 Tranylcypromine is a non hydrazine monoamine oxidase 
inhibitor used in psychiatry40 and has proven inhibitory activity towards many CYPs.1 Previously 
published studies on human liver microsomes or cDNA expressing microsomes have reported 
the inhibition of CYP2A6 activity towards coumarin 7-hydroxylation by tranylcypromine, with 
calculated Ki values ranging from 0.04 to 0.42 µM.1,40,41 Here we used CYP2A6-FLD glassy 
carbon electrodes to investigate the inhibition of coumarin metabolism by tranylcypromine. 
 
 
Figure 5. Tranylcypromine concentration-dependent inhibition of coumarin 7-hydroxylation by 
CYP2A6-FLD modified glassy carbon electrodes. Data are shown as mean ± SD of three 
different electrodes. 
 
The inhibition profile of CYP2A6-FLD coumarin 7-hydroxylation by tranylcypromine is 
shown in Figure 5. The calculated IC50 value was 3.1 ± 0.6 µM. Using Cheng and Prusoff 
relationship for competitive inhibition,42 the calculated IC50 value was also converted to Ki 
obtaining a value of 0.29 ± 0.06 µM which is in good agreement with previously published 
results using microsomes.1,40,41 
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In addition, inhibition experiments in the presence of tranylcypromine were also performed 
using nicotine as substrate. In humans, about 70 to 80% of nicotine is converted to cotinine in 
two enzymatic steps. The first is nicotine 5’-oxidation mediated by CYP2A6. Secondly, Δ1’(5’)-
iminium ion product of this reaction is further metabolised to cotinine by aldehyde oxidase.6,43,44 
Here we firstly calculated KM value by performing electrocatalysis of nicotine on CYP2A6-FLD 
glassy carbon electrodes. The estimated KM value was 131.4 ± 52.2 µM, in agreement with 
previously published results on microsomal CYP2A6 protein [44]. Then we used CYP2A6-FLD 
glassy carbon electrodes to investigate the inhibition of nicotine metabolism by tranylcypromine. 
The inhibition profile of CYP2A6-FLD nicotine 5’- oxidation by tranylcypromine is shown in 
Figure 6. 
 
 
Figure 6. Tranylcypromine concentration-dependent inhibition of nicotine 5’-oxidation by 
CYP2A6-FLD modified glassy carbon electrodes. Data are shown as mean ± SD of three 
different electrodes. 
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The calculated IC50 value was 3.7 ± 0.2 µM. Using Cheng and Prusoff relationship for 
competitive inhibition,42 the calculated IC50 value was also converted to Ki obtaining a value of 
1.72 ± 0.09 µM. No available literature data about tranylcypromine inhibition of CYP2A6 5’-
oxidation of nicotine were found for the comparison of our results. 
 
CONCLUSIONS	  
 
In conclusion, for the first time a bio-electrochemical set up suitable for the investigation of 
CYP2A6 catalytic activity has been developed by immobilising on glassy carbon electrodes the 
chimeric form of the enzyme CYP2A6-FLD obtained by genetically fusing CYP2A6 with FLD. 
The fusion protein showed an improved catalytic efficiency in agreement with what has been 
previously reported for CYP3A420 where the regulation of the electron flow to the haem through 
FLD resulted in an increase of product formation due to an enhancement of the coupling 
efficiency. It was also demonstrated that the increase in catalytic activity observed for CYP2A6-
FLD when compared to CYP2A6 could be related to the improved control of the enzyme 
coupling efficiency and to a more refined electron flow tuning. The CYP2A6 based bio-
electrochemical platform was also successfully used to test enzymatic inhibition in the presence 
of its well known inhibiting drug, proving the suitability of this system for the screening of 
inhibitors of this enzyme, highly relevant to nicotine addiction treatment. Finally, this molecular 
engineering approach can aid in the development of improved electrochemical sensors based on 
CYP enzymes for drug screening and metabolic profiling. 
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